journal article·2018-11-05Open access

Engineering of pectin-capped gold nanoparticles for delivery of doxorubicin to hepatocarcinoma cells: an insight into mechanism of cellular uptake

Shaivee Borker, Varsha Pokharkar

Abstract

In this study, we have reported the fabrication and evaluation of pectin-capped gold nanoparticles (PEC-AuNPs) for delivery of anticancer drug, doxorubicin (DOX) to cells overexpressing asialoglycoprotein receptor (ASGPR). Pectin was used as a reducing, stabilizing and targeting agent. The pectin-capped gold nanoparticles demonstrated surface plasmon resonance band at 519 nm. The PEC-AuNPs were spherical in shape with a particle size of 14 nm and zeta potential value of -33 mV and were biocompatible and non-cytotoxic. The PEC-AuNPs exhibited a high drug loading efficiency of 78%. The DOX-loaded gold nanoparticles (DOX-PEC-AuNPs) showed excellent stability under varying pH and electrolytic conditions. The cytotoxicity study of the DOX-PEC-AuNPs in human Caucasian hepatocyte cells demonstrated their greater potency in killing these cells as compared to free DOX. The uptake and targeting potential of DOX-PEC-AuNPs was thoroughly investigated. Further, it was found that the PEC-AuNPs were taken up by HepG2 cells via a clathrin-dependent receptor-mediated endocytosis by asialoglycoprotein receptor present of the surface of these cells. Thus, the PEC-capped AuNPs can prove a promising carrier for anticancer drug in the treatment of hepatocellular carcinoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Bharati Vidyapeeth Deemed University Poona College of Pharmacy, Pune, India

References (36)

Show source-provided references
1. 10.2217/17435889.2.1.11310.2217/17435889.2.1.113 ↗
2. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
3. 10.1080/21691401.2017.140801910.1080/21691401.2017.1408019 ↗
4. 10.3109/21691401.2014.95510710.3109/21691401.2014.955107 ↗
5. 10.1021/ar100048c10.1021/ar100048c ↗
6. 10.1016/j.addr.2008.03.01610.1016/j.addr.2008.03.016 ↗
7. 10.1002/smll.20040009310.1002/smll.200400093 ↗
8. 10.2217/fvl-2015-001010.2217/fvl-2015-0010 ↗
9. 10.1021/ja906506j10.1021/ja906506j ↗
10. 10.1021/la702151q10.1021/la702151q ↗
11. 10.3109/21691401.2015.111541010.3109/21691401.2015.1115410 ↗
12. 10.1080/21691401.2017.130721310.1080/21691401.2017.1307213 ↗
13. 10.1002/chem.20080109310.1002/chem.200801093 ↗
14. 10.1016/j.carbpol.2014.03.04110.1016/j.carbpol.2014.03.041 ↗
15. 10.1021/la051982u10.1021/la051982u ↗
16. 10.1007/s13404-017-0213-010.1007/s13404-017-0213-0 ↗
17. 10.1002/ijc.2921010.1002/ijc.29210 ↗
18. World Health Organization. Cancer factsheet. 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/cancer (last accessed 22 January 2018).
19. 10.1200/JOP.2011.00036410.1200/JOP.2011.000364 ↗
20. 10.1038/nrc156610.1038/nrc1566 ↗
21. 10.1093/annonc/mdf30310.1093/annonc/mdf303 ↗
22. 10.1016/j.nano.2009.02.00210.1016/j.nano.2009.02.002 ↗
23. 10.1016/j.jconrel.2015.02.02210.1016/j.jconrel.2015.02.022 ↗
24. 10.1016/j.ijpharm.2006.06.03410.1016/j.ijpharm.2006.06.034 ↗
25. 10.1080/10717544.2016.122585610.1080/10717544.2016.1225856 ↗
26. 10.1021/mp400412c10.1021/mp400412c ↗
27. 10.1097/CAD.0b013e328351424f10.1097/CAD.0b013e328351424f ↗
28. 10.1016/j.ejps.2012.02.00710.1016/j.ejps.2012.02.007 ↗
29. 10.1166/jnn.2015.903910.1166/jnn.2015.9039 ↗
30. 10.1021/nl070363y10.1021/nl070363y ↗
31. 10.1016/j.bbrc.2010.02.04610.1016/j.bbrc.2010.02.046 ↗
32. 10.1016/j.ijpharm.2008.04.02910.1016/j.ijpharm.2008.04.029 ↗
33. 10.1021/la950271110.1021/la9502711 ↗
34. Teodora M. · Biotechnol Mol Biol Nanomed · 2013 · 1 · 7
35. 10.1021/bc049951i10.1021/bc049951i ↗
36. 10.1021/nn200007z10.1021/nn200007z ↗